ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) Current ratio
ResMed Inc.'s current ratio at the end of the quarter to 30 June 2026 was 3.1×. Over the past ten years it has ranged from 1.7× (fiscal 2021) to 5.3× (fiscal 2015); the current reading is higher than 67% of that period. That is above the Medical Instruments & Supplies industry median of 2.5× and in line with the Healthcare sector median of 3.0×.
Current ratio, annual
Annual
| Period | Current ratio | Change |
|---|---|---|
| FY2026 | 3.1× | (9.88%) |
| FY2025 | 3.4× | 32.86% |
| FY2024 | 2.6× | (17.06%) |
| FY2023 | 3.1× | 11.40% |
| FY2022 | 2.8× | 62.23% |
| FY2021 | 1.7× | (31.66%) |
| FY2020 | 2.5× | 22.69% |
| FY2019 | 2.1× | (1.18%) |
| FY2018 | 2.1× | (54.34%) |
| FY2017 | 4.6× | 105.15% |
Quarterly
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 3.1× | 3.07% |
| Mar 2026 | 3.0× | (1.70%) |
| Dec 2025 | 3.1× | 5.95% |
| Sep 2025 | 2.9× | (16.04%) |
| 42 more quarters | Free account |
Against its own ten years
Low 1.7×
High 5.3×
Ten-year median
2.7×
Current reading's percentile
67
Current ratio against peers
| Company | Current ratio |
|---|---|
| RGEN Repligen Corporation compare | 9.1× |
| MDLN Medline Inc. compare | 4.3× |
| RMD ResMed Inc. | 3.1× |
| WST West Pharmaceutical Services, Inc. compare | 2.8× |
| ALC Alcon compare | 2.1× |
| BAX Baxter International Inc. compare | 1.9× |
| COO The Cooper Companies, Inc. compare | 1.2× |
| SOLV Solventum Corporation compare | 1.0× |
| BDX Becton, Dickinson and Company compare | 0.9× |
| Medical Instruments & Supplies industry median | 2.5× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement